11034 studies found for:    NCI
Show Display Options
Rank Status Study
21 Not yet recruiting Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Serous Tumor;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: ATR Kinase Inhibitor VX-970;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis
22 Not yet recruiting Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vulvar Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IB Vulvar Cancer;   Stage IB2 Cervical Cancer;   Stage II Vulvar Cancer;   Stage IIA1 Cervical Cancer;   Stage IIA2 Cervical Cancer;   Stage IIB Cervical Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Vulvar Cancer;   Stage IIIB Cervical Cancer;   Stage IIIB Vulvar Cancer;   Stage IIIC Vulvar Cancer;   Stage IVA Cervical Cancer;   Stage IVA Vulvar Cancer;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: High-Dose Rate Brachytherapy;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Triapine
23 Recruiting Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
Conditions: AIDS-Related Non-Hodgkin Lymphoma;   Classical Hodgkin Lymphoma;   HIV Infection;   Kaposi Sarcoma;   Locally Advanced Malignant Neoplasm;   Metastatic Malignant Neoplasm;   Recurrent Hepatocellular Carcinoma;   Recurrent Hodgkin Lymphoma;   Recurrent Kaposi Sarcoma;   Recurrent Malignant Neoplasm;   Recurrent Melanoma;   Recurrent Melanoma of the Skin;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Non-Small Cell Lung Carcinoma;   Refractory Hodgkin Lymphoma;   Refractory Malignant Neoplasm;   Solid Neoplasm;   Stage IIIA Hepatocellular Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Hepatocellular Carcinoma;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Hepatocellular Carcinoma;   Stage IIIC Skin Melanoma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Skin Melanoma;   Stage IVA Hepatocellular Carcinoma;   Stage IVB Hepatocellular Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
24 Not yet recruiting VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer
Conditions: Lung Carcinoma Metastatic in the Brain;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: ATR Kinase Inhibitor VX-970;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Procedure: Therapeutic Conventional Surgery;   Radiation: Whole-Brain Radiotherapy
25 Not yet recruiting Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma
Conditions: Metastatic Melanoma;   Recurrent Melanoma of the Skin;   Stage IV Skin Melanoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study
26 Not yet recruiting Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
Conditions: Erythroplakia;   Hyperplasia;   Mild Dysplasia;   Moderate Dysplasia;   Oral Cavity Carcinoma;   Oral Leukoplakia;   Severe Dysplasia
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Metformin Hydrochloride
27 Recruiting AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma
Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mantle Cell Lymphoma
Interventions: Other: Fluorothymidine F-18;   Drug: Hsp90 Inhibitor AT13387;   Other: Laboratory Biomarker Analysis;   Procedure: Positron Emission Tomography
28 Recruiting Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants
Conditions: Human Papillomavirus Infection;   No Evidence of Disease
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Recombinant Human Papillomavirus Nonavalent Vaccine
29 Not yet recruiting Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Mediastinal Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma
Interventions: Biological: Blinatumomab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
30 Not yet recruiting Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
Conditions: Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma;   Untreated Childhood Rhabdomyosarcoma
Interventions: Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate
31 Not yet recruiting VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma
Conditions: Head and Neck Squamous Cell Carcinoma;   Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma
Interventions: Drug: ATR Kinase Inhibitor VX-970;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy
32 Not yet recruiting Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer
Conditions: Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter;   Stage IV Bladder Urothelial Carcinoma
Interventions: Drug: ATR Kinase Inhibitor VX-970;   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis
33 Not yet recruiting Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Conditions: Estrogen Receptor Negative;   Head and Neck Squamous Cell Carcinoma;   HER2/Neu Negative;   Hormone-Resistant Prostate Cancer;   Metastatic Pancreatic Adenocarcinoma;   Progesterone Receptor Negative;   Solid Neoplasm;   Stage III Mesothelioma;   Stage IIIA Gastric Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Small Cell Lung Carcinoma;   Stage IIIB Gastric Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Small Cell Lung Carcinoma;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Mesothelioma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Ovarian Cancer;   Stage IV Small Cell Lung Carcinoma;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib
34 Recruiting Erlotinib Hydrochloride and Hsp90 Inhibitor AT13387 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Drug: Hsp90 Inhibitor AT13387;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
35 Recruiting Methoxyamine, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer
Conditions: Metastatic Malignant Neoplasm in the Brain;   Stage IIIA Large Cell Lung Carcinoma;   Stage IIIA Lung Adenocarcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Large Cell Lung Carcinoma;   Stage IIIB Lung Adenocarcinoma;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Large Cell Lung Carcinoma;   Stage IV Lung Adenocarcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Methoxyamine;   Drug: Pemetrexed Disodium
36 Recruiting Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Cisplatin and Pemetrexed
Conditions: Advanced Peritoneal Malignant Mesothelioma;   Advanced Pleural Malignant Mesothelioma;   Recurrent Peritoneal Malignant Mesothelioma;   Recurrent Pleural Malignant Mesothelioma;   Solid Neoplasm;   Stage III Pleural Mesothelioma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Ovarian Cancer;   Stage IV Pleural Mesothelioma;   Thymoma
Interventions: Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Drug: Methoxyamine;   Drug: Pemetrexed Disodium;   Other: Pharmacological Study
37 Recruiting Acetylsalicylic Acid in Preventing Disease Recurrence in Patients With Barrett's Esophagus After Successful Elimination by Radiofrequency Ablation
Conditions: Barrett Esophagus;   Barrett Esophagus-Negative for Dysplasia;   Dysplasia in Barrett Esophagus
Interventions: Drug: Aspirin;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Questionnaire Administration
38 Recruiting Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
Conditions: Follicular Variant Peripheral T-Cell Lymphoma;   Recurrent Angioimmunoblastic T-cell Lymphoma;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Refractory Angioimmunoblastic T-cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Interventions: Biological: Anti-ICOS Monoclonal Antibody MEDI-570;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
39 Recruiting EGFR Inhibitor AZD9291 and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Navitoclax;   Drug: Osimertinib;   Other: Pharmacological Study
40 Recruiting High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
Conditions: Metastatic Non-Cutaneous Melanoma;   Non-Cutaneous Melanoma;   Recurrent Melanoma of the Skin;   Recurrent Non-Cutaneous Melanoma;   Stage III Mucosal Melanoma of the Head and Neck;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma;   Stage IVA Mucosal Melanoma of the Head and Neck;   Stage IVB Mucosal Melanoma of the Head and Neck;   Stage IVC Mucosal Melanoma of the Head and Neck
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years